{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T06:37:27Z","timestamp":1759991847856},"reference-count":36,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2004,3,1]],"date-time":"2004-03-01T00:00:00Z","timestamp":1078099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gastroenterology Clinics of North America"],"published-print":{"date-parts":[[2004,3]]},"DOI":"10.1016\/j.gtc.2003.12.002","type":"journal-article","created":{"date-parts":[[2005,4,18]],"date-time":"2005-04-18T14:53:30Z","timestamp":1113836010000},"page":"25-35","source":"Crossref","is-referenced-by-count":21,"special_numbering":"S","title":["Role of epoetin alfa in maintaining ribavirin dose"],"prefix":"10.1016","volume":"33","author":[{"given":"Nezam H.","family":"Afdhal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.gtc.2003.12.002_BIB1","first-page":"S3","article-title":"National Institutes of Health Consensus Development Conference statement: management of hepatitis C: 2002. June 10\u201312, 2002","volume":"36","author":"Boyer","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.gtc.2003.12.002_BIB2","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1053\/gast.2002.35950","article-title":"Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C","volume":"123","author":"McHutchison","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2003.12.002_BIB3","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.gtc.2003.12.002_BIB4","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.gtc.2003.12.002_BIB5","doi-asserted-by":"crossref","first-page":"S237","DOI":"10.1002\/hep.1840360730","article-title":"Side effects of therapy of hepatitis C and their management","volume":"36","author":"Fried","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.gtc.2003.12.002_BIB6","series-title":"PEG-Intron (peginterferon alfa-2b) powder for injection: prescribing information","year":"2001"},{"key":"10.1016\/j.gtc.2003.12.002_BIB7","series-title":"PEGASYS (peginterferon alfa-2a) prescribing information","year":"2002"},{"key":"10.1016\/j.gtc.2003.12.002_BIB8","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/0002-9343(84)90282-1","article-title":"Changes in the bone marrow of cancer patients treated with recombinant interferon alpha-2","volume":"76","author":"Ernstoff","year":"1984","journal-title":"Am J Med"},{"key":"10.1016\/j.gtc.2003.12.002_BIB9","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1182\/blood.V70.4.1173.1173","article-title":"Effect of recombinant interferons alpha and gamma on human bone marrow-derived megakaryocytic progenitor cells","volume":"70","author":"Ganser","year":"1987","journal-title":"Blood"},{"key":"10.1016\/j.gtc.2003.12.002_BIB10","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1053\/gast.2002.34175","article-title":"Rapid suppression of hematopoiesis by standard or pegylated interferon-\u03b1","volume":"123","author":"Peck-Radosavljevic","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2003.12.002_BIB11","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1053\/jhep.2002.36502","article-title":"Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C","volume":"36","author":"Soza","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.gtc.2003.12.002_BIB12","first-page":"907","article-title":"Combination treatment of advanced HCV associated liver disease with interferon and G-CSF","volume":"42","author":"Van Thiel","year":"1995","journal-title":"Hepatogastroenterology"},{"key":"10.1016\/j.gtc.2003.12.002_BIB13","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1111\/j.1440-1746.1996.tb00023.x","article-title":"Case report: agranulocytosis induced by interferon-alpha therapy for chronic hepatitis C","volume":"11","author":"Higashi","year":"1996","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.gtc.2003.12.002_BIB14","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S0168-8278(98)80310-3","article-title":"Use of granulocyte macrophage colony stimulating factor alone or in combination with interferon-alpha-2b for treatment of chronic hepatitis C","volume":"28","author":"Shiffman","year":"1998","journal-title":"J Hepatol"},{"key":"10.1016\/j.gtc.2003.12.002_BIB15","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1080\/mccm.6.3.149.154","article-title":"Effects of interferon-alpha on peripheral neutrophil counts and serum granulocyte colony-stimulating factor levels in chronic hepatitis C patients","volume":"6","author":"Fukuda","year":"2000","journal-title":"Cytokines Cell Mol Ther"},{"key":"10.1016\/j.gtc.2003.12.002_BIB16","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1006\/cyto.1999.0530","article-title":"Randomized controlled trial of recombinant human granulocyte-macrophage colony-stimulating factor for the treatment of chronic hepatitis C","volume":"12","author":"Carre\u00f1o","year":"2000","journal-title":"Cytokine"},{"key":"10.1016\/j.gtc.2003.12.002_BIB17","series-title":"Intron A (interferon alfa-2b, recombinant) for injection: prescribing information","year":"2001"},{"key":"10.1016\/j.gtc.2003.12.002_BIB18","series-title":"Roferon-A (interferon alfa-2a, recombinant: prescribing information)","year":"2003"},{"key":"10.1016\/j.gtc.2003.12.002_BIB19","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/jama.266.6.849","article-title":"Thrombocytopenia during interferon alfa therapy","volume":"266","author":"Hoofnagle","year":"1991","journal-title":"JAMA"},{"issue":"4 Pt 2","key":"10.1016\/j.gtc.2003.12.002_BIB20","first-page":"361A","article-title":"Safety and efficacy of recombinant human IL-11 (oprelvekin) in combination with interferon\/ribavirin therapy in hepatitis C patients with thrombocytopenia","volume":"36","author":"Rustgi","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.gtc.2003.12.002_BIB21","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1002\/hep.510260231","article-title":"Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial","volume":"26","author":"Bodenheimer","year":"1997","journal-title":"Hepatology"},{"key":"10.1016\/j.gtc.2003.12.002_BIB22","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1053\/he.2000.5789","article-title":"Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage","volume":"31","author":"De Franceschi","year":"2000","journal-title":"Hepatology"},{"issue":"4 Suppl 1","key":"10.1016\/j.gtc.2003.12.002_BIB23","doi-asserted-by":"crossref","first-page":"A-751","DOI":"10.1016\/S0016-5085(03)83793-9","article-title":"Erythropoietic response to anemia is decreased in patients infected with hepatitis C virus (HCV) receiving combination ribavirin and pegylated interferon (RBV\/PEG-IFN) therapy","volume":"124","author":"Balan","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2003.12.002_BIB24","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1001\/jama.261.21.3104","article-title":"Serum immunoreactive erythropoietin in HIV-infected patients","volume":"261","author":"Spivak","year":"1989","journal-title":"JAMA"},{"key":"10.1016\/j.gtc.2003.12.002_BIB25","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJM199006143222401","article-title":"Decreased erythropoietin response in patients with the anemia of cancer","volume":"322","author":"Miller","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gtc.2003.12.002_BIB26","series-title":"COPEGUS (ribavirin, USP) tablets: prescribing information","year":"2002"},{"key":"10.1016\/j.gtc.2003.12.002_BIB27","series-title":"Rebetron combination therapy containing Rebetol (ribavirin, USP) capsules and Intron A (interferon alfa-2b, recombinant) injection: prescribing information","year":"2002"},{"key":"10.1016\/j.gtc.2003.12.002_BIB28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2893.2004.00490.x","article-title":"Changes in hemoglobin during interferon alfa-2b plus ribavirin combination therapy for chronic hepatitis C virus infection","volume":"11","author":"Sulkowski","year":"2004","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.gtc.2003.12.002_BIB29","first-page":"L87","article-title":"Ribavirin serum concentration rather than dose per body weight determines the extent of anaemia in the treatment of chronic hepatitis C","volume":"7","author":"Lindahl","year":"2002","journal-title":"Antivir Ther"},{"key":"10.1016\/j.gtc.2003.12.002_BIB30","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/00007691-200010000-00010","article-title":"Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C","volume":"22","author":"Jen","year":"2000","journal-title":"Ther Drug Monit"},{"issue":"4 Pt 2","key":"10.1016\/j.gtc.2003.12.002_BIB31","first-page":"295A","article-title":"Retreatment of HCV non-responders with peginterferon and ribavirin: results from the lead-in phase of the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial","volume":"36","author":"Shiffman","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.gtc.2003.12.002_BIB32","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1046\/j.1524-4733.2001.45075.x","article-title":"Management strategies for ribavirin-induced hemolytic anemia in the treatment of hepatitis C: clinical and economical implications","volume":"4","author":"Devine","year":"2001","journal-title":"Value Health"},{"key":"10.1016\/j.gtc.2003.12.002_BIB33","first-page":"2802","article-title":"A preliminary study of erythropoietin for anemia associated with ribavirin and interferon-\u03b1","volume":"96","author":"Talal","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gtc.2003.12.002_BIB34","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1053\/jhep.2002.32529","article-title":"Treatment of ribavirin\/interferon-induced anemia with erythropoietin in patients with hepatitis C [letter]","volume":"35","author":"Gergely","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.gtc.2003.12.002_BIB35","first-page":"2491","article-title":"Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa","volume":"98","author":"Dieterich","year":"2003","journal-title":"Am J Gastroenterol"},{"issue":"4 Suppl 1","key":"10.1016\/j.gtc.2003.12.002_BIB36","doi-asserted-by":"crossref","first-page":"A-714","DOI":"10.1016\/S0016-5085(03)83605-3","article-title":"Epoetin alfa treatment of anemic HCV-infected patients allows for maintenance of ribavirin dose, increases hemoglobin levels, and improves quality of life vs placebo: a randomized, double-blind, multicenter study","volume":"124","author":"Afdhal","year":"2003","journal-title":"Gastroenterology"}],"container-title":["Gastroenterology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889855303001365?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889855303001365?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,6]],"date-time":"2020-04-06T22:51:31Z","timestamp":1586213491000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889855303001365"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,3]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,3]]}},"alternative-id":["S0889855303001365"],"URL":"https:\/\/doi.org\/10.1016\/j.gtc.2003.12.002","relation":{},"ISSN":["0889-8553"],"issn-type":[{"value":"0889-8553","type":"print"}],"subject":[],"published":{"date-parts":[[2004,3]]}}}